The FDA's Pharmacy Compounding Advisory Committee has meetings scheduled for July 2026 to formally review them for Category 1 placement
If you are considering fillers and not sure who to trust, Aminda and Leslie are ARTISTS
That being said, the high doses of the nootropic measured at 0.5 mg/kg/day for intraperitoneal delivery and 2.0 mg/kg/day for oral delivery, and resulted in a performance that was indistinguishable from the control group and significantly better than the animals treated with scopolamine alone [2]
Those publications include fewer than 40 actual humans, there is no identified high-affinity receptor for BPC-157 in the human body, and no randomized trial has ever demonstrated any evidence that it works
However, more research is needed to establish causal relationships and understand the clinical significance of these observations
[DOI] [PubMed] [Google Scholar] 27.Liu Z., Huang J., Kang D., Zhou Y., Du L., Qu Q., Wang J., Wen L., Fu D., Hu Z., et al